---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-24-000022"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:30:04.590625+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences Transfers to Nasdaq Capital Market, Gets Second Compliance Period

## Summary
- On Jan 23, 2024, Nasdaq approved transfer of Senti Biosciences common stock from Global Market to Capital Market, effective Jan 25.
- Nasdaq granted a second 180-day period until Aug 5, 2024, to meet $1.00 bid price requirement.
- Company must show closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
- If not compliant by Aug 5, 2024, Nasdaq will delist SNTI; company may appeal to Hearings Panel.
- Senti Biosciences intends to consider a reverse stock split to cure the bid price deficiency.

## SEC filing metadata
- accession: 0001854270-24-000022
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000022/0001854270-24-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000022/snti-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-24-000022
- JSON: https://secwatch.observer/filing/0001854270-24-000022.json
- Plain text: https://secwatch.observer/filing/0001854270-24-000022.txt

## Key facts
- Listing & Compliance Notices
  Senti Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: February 6, 2024, the Staff granted the Company’s request for a second 180-calendar day period, or until August 5, 2024 (the “Second Compliance Period”), to regain compliance with the $1.00 bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with such minimum price requirement, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. The transfer of the listing of the Company’s Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect with the open of business on Ja
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427024000022/0001854270-24-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.